![]() |
市场调查报告书
商品编码
1755978
2032 年弹性成像市场预测:按模式、技术、应用和地区分類的全球分析Elastography Imaging Market Forecasts to 2032 - Global Analysis By Modality (Ultrasound Elastography and Magnetic Resonance Elastography (MRE)), Technology (Strain Elastography, Shear Wave Elastography), Application and By Geography |
根据 Stratistics MRC 的数据,全球弹性成像市场预计在 2025 年达到 24.9 亿美元,到 2032 年将达到 46.5 亿美元,预测期内的复合年增长率为 9.32%。
一种名为弹性成像的非侵入性医学成像技术,透过测量组织弹性或硬度来检测异常。为了检测改变组织硬度的疾病,例如肝纤维化或肿瘤,需要对组织施加机械力,并观察其如何变形。弹性成像通常与核磁共振成像 (MRI) 或超音波结合使用,以提供定量的即时数据,从而更早发现疾病并提高诊断准确性。弹性成像在肌肉骨骼成像、肝病学和癌症领域特别有用,它提供了一种比侵入性切片检查技术更准确、更安全的替代方案。
慢性肝病和癌症增加
弹性成像是一种精准、非侵入性的方法来识别肝臟肿瘤和纤维化,从而促进早期诊断和治疗。全球肝硬化、脂肪肝和肝炎的发生率不断上升,推动了对先进成像技术的需求。弹性成像能够测量组织硬度,也能透过表征肿瘤特征使癌症患者受益。为了改善患者预后并减少切片检查需求,医疗保健提供者越来越多地使用这项技术。因此,弹性成像在医院和诊断机构的临床应用中越来越被接受。
弹性成像系统高成本
弹性成像系统需要大量的初始投资,许多医疗机构难以承受。此外,维护和营运成本对于资源匮乏的医疗机构来说也是一笔额外的负担。资金限制迫使小型医院和诊断机构选择传统的影像技术。这一高昂的成本限制制约了先进弹性成像技术的市场渗透。因此,弹性成像市场的整体成长潜力受到抑制。
科技进步与人工智慧的融合
人工智慧 (AI) 与机器学习技术正在融合,以变革影像分析。透过自动化影像解读和识别人眼可能遗漏的细微异常,人工智慧提高了诊断的准确性。这带来了更具可重复性的观察,并减少了对操作人员的依赖。人工智慧还可以指导治疗并促进即时影像品质评估。随着人工智慧、巨量资料和云端运算的结合,提供日益全面和准确的诊断能力,全球市场预计将进一步扩大。
缺乏训练有素的专业人员和标准化通讯协定
这项技术学习难度高,令许多医疗从业人员犹豫不决。训练设施不足进一步加剧了不同地区医疗能力的差异。此外,缺乏标准化的影像技术导致治疗结果参差不齐,诊断可靠性降低。这些不一致性阻碍了它在标准医疗实践中的广泛应用。因此,营运效率低和用户质疑都限制了市场扩张。
COVID-19的影响
新冠疫情对弹性成像市场造成了重大衝击。由于择期手术延迟以及医疗保健重点转向疫情防治,该市场最初出现下滑。供应链中断和产能下降进一步阻碍了市场成长。然而,随着医疗体系的调整,需求逐渐回升,尤其是在弹性成像技术被证明可用于评估长期新冠患者肺纤维化等器官损伤方面。对非侵入性诊断的日益关注以及推迟检测的积压,正在推动市场稳步復苏和成长。
超音波弹性成像市场预计将在预测期内成长至最大
预计超音波弹性成像领域将在预测期内占据最大的市场占有率,因为与MRI等其他成像方式相比,它具有非侵入性和成本效益的特性。弹性成像可以即时可视化并定量评估组织硬度,有助于早期发现和监测疾病。肝病和乳癌等慢性疾病的盛行率不断上升,进一步推动了其作为首选诊断工具的应用。与传统超音波相比,它能够提供更多信息,尤其是在识别恶性组织方面,从而减少了侵入性切片检查的需求。此外,技术的不断进步和医疗专业人员意识的不断提高,正在不断扩大其临床应用和市场规模。
心臟病学领域预计在预测期内以最高复合年增长率成长
循环系统领域需要先进的诊断工具,预计在预测期内将达到最高成长率。弹性成像技术提供了一种非侵入性方法来评估心肌僵硬程度并识别纤维化变化,这对于早期发现疾病至关重要。它能够量化组织弹性,为诊断心臟衰竭和心肌病等疾病提供宝贵的见解。此外,对超越传统成像模式的全面心臟评估的需求日益增长,这推动了弹性成像技术的普及。因此,弹性成像已成为心血管诊断中日益重要的工具,为市场成长做出了重大贡献。
在预测期内,亚太地区预计将占据最大的市场占有率,这得益于医疗基础设施投资的增加以及人们对疾病早期诊断意识的不断增强。肝病、癌症和慢性病盛行率的上升刺激了对先进成像技术的需求。中国、日本和印度等国家正在医院和诊断环境中迅速采用弹性成像技术。技术进步加上老年人口的成长,支撑了长期成长前景。此外,有利的政府政策和日益增长的医疗旅游也进一步推动了该地区市场的扩张。
在预测期内,由于创新诊断技术的早期应用,北美地区预计将呈现最高的复合年增长率。领先的医疗设备製造商和研究机构的强大影响力有助于持续的产品开发。乳癌、肝纤维化和心血管疾病的发生率不断上升,推动了弹性成像的临床应用。高昂的医疗支出、强大的保险覆盖范围以及完善的法律规范正在推动市场持续成长。美国在该区域市场占据主导地位,受益于技术整合、熟练的专业人员以及对非侵入式成像解决方案日益增长的需求。
According to Stratistics MRC, the Global Elastography Imaging Market is accounted for $2.49 billion in 2025 and is expected to reach $4.65 billion by 2032 growing at a CAGR of 9.32% during the forecast period. A non-invasive medical imaging method called elastography imaging gauges the elasticity or stiffness of tissues to find anomalies. In order to detect disorders where tissue stiffness varies, such as liver fibrosis and tumours, it applies mechanical force to tissues and examines how they deform in response. Elastography, which is frequently utilised in conjunction with MRI or ultrasound, offers quantitative, real-time data that improves early disease identification and diagnostic precision. It is particularly useful in musculoskeletal imaging, hepatology, and cancer, providing a more accurate and safer substitute for invasive biopsy techniques.
Rising prevalence of chronic liver diseases and cancer
Elastography provides a precise and non-invasive way to identify liver tumours and fibrosis, facilitating early diagnosis and therapy. The need for sophisticated imaging technologies is fuelled by rising rates of cirrhosis, fatty liver disease, and hepatitis worldwide. Elastography's capacity to measure tissue stiffness also helps cancer patients by enhancing tumour characterisation. In an effort to improve patient outcomes and lessen the necessity for biopsies, healthcare providers are using this technology more and more. Elastography imaging is therefore becoming increasingly clinically accepted in hospitals and diagnostic facilities.
High cost of elastography imaging systems
A large initial investment is frequently needed for these systems, which many healthcare organisations cannot afford. Institutions with tight resources are further burdened by maintenance and operating expenses. Because of financial limitations, smaller hospitals and diagnostic facilities could choose traditional imaging techniques. The market penetration of sophisticated elastography technologies is constrained by this expensive hurdle. Consequently, the elastography imaging market's overall growth potential is impeded.
Technological advancements and integration with AI
Artificial Intelligence (AI) and machine learning technologies are being combined to transform picture analysis. By automating image interpretation and identifying minor anomalies that the human eye frequently misses, artificial intelligence improves diagnosis accuracy. As a result, findings are more reproducible and operator dependence is decreased. AI also directs treatments and makes it easier to evaluate image quality in real time. Global market increase is anticipated as AI, big data, and cloud computing combine to provide increasingly more thorough and accurate diagnostic capabilities.
Lack of skilled professionals and standardized protocols
The high learning curve associated with the technology makes many healthcare practitioners hesitant to invest in it. The disparity in competence between locations is further widened by inadequate training facilities. Furthermore, variable outcomes and decreased diagnostic confidence are caused by the lack of standardised imaging techniques. Wider incorporation into standard medical practice is discouraged by this discrepancy. Consequently, both operational inefficiency and user scepticism limit market expansion.
Covid-19 Impact
The COVID-19 pandemic significantly impacted the elastography imaging market. Initially, there was a downturn due to deferred elective procedures and a shift in healthcare priorities towards managing the pandemic. Supply chain disruptions and reduced manufacturing capabilities further hindered market growth. However, as healthcare systems adapted, there was a resurgence in demand, particularly as elastography proved valuable in assessing organ damage, including lung fibrosis in long-COVID patients. The increased focus on non-invasive diagnostic methods and the backlog of postponed examinations are now driving a steady recovery and growth in the market.
The ultrasound elastography segment is expected to be the largest during the forecast period
The ultrasound elastography segment is expected to account for the largest market share during the forecast period, due to its non-invasive nature and cost-effectiveness compared to other imaging modalities like MRI. It offers real-time visualization and quantitative assessment of tissue stiffness, aiding in early disease detection and monitoring. The growing prevalence of chronic conditions like liver diseases and breast cancer further drives its adoption as a preferred diagnostic tool. Its ability to provide additional information beyond conventional ultrasound, particularly in identifying malignant tissues, reduces the need for invasive biopsies. Moreover, ongoing technological advancements and increasing awareness among healthcare professionals are continuously expanding its clinical applications and market reach.
The cardiology segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cardiology segment is predicted to witness the highest growth rate, due to necessitating advanced diagnostic tools. Elastography offers a non-invasive method for assessing myocardial stiffness and identifying fibrotic changes, crucial for early disease detection. Its ability to quantify tissue elasticity provides valuable insights for diagnosing conditions like heart failure and cardiomyopathy. Furthermore, the rising demand for comprehensive cardiac assessments that go beyond traditional imaging methods fuels its adoption. This makes elastography an increasingly vital tool in cardiovascular diagnostics, significantly contributing to the market's growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by increasing investments in healthcare infrastructure and rising awareness about early disease diagnosis. Growing prevalence of liver diseases, cancer, and chronic conditions fuels demand for advanced imaging technologies. Countries like China, Japan, and India are rapidly adopting elastography in both hospital and diagnostic settings. Technological advancements, coupled with expanding geriatric populations, support long-term growth prospects. Moreover, favorable government policies and expanding medical tourism further accelerate market expansion in the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to early adoption of innovative diagnostic technologies. Strong presence of major healthcare equipment manufacturers and research institutions contributes to continuous product development. Rising incidence of breast cancer, liver fibrosis, and cardiovascular diseases encourages clinical use of elastography. High healthcare spending, robust insurance coverage, and established regulatory frameworks drive consistent market growth. The U.S. dominates the regional market, benefiting from technological integration, skilled professionals, and increasing demand for non-invasive imaging solutions.
Key players in the market
Some of the key players profiled in the Elastography Imaging Market include Canon Medical Systems Corporation, GE HealthCare, Koninklijke Philips N.V., FUJIFILM Corporation, Mindray Medical International Limited, Esaote S.p.A, Siemens Healthineers, Hitachi, Ltd., Samsung Medison Co., Ltd., SuperSonic Imagine, Resoundant, Inc., Hologic, Inc., Toshiba America Medical Systems, Inc., Clarius Mobile Health, Carestream Health, Advanced Instrumentations, BK Medical Holding Company, Inc. and SonoScape Medical Corp.
In January 2025, GE HealthCare strengthened its partnership with the ESR as a Platinum Supporter for ECR 2025. This expanded collaboration focuses on redefining medical imaging innovation. The partnership emphasizes precision care, innovation and sustainability in radiology, all of which are highly relevant to elastography imaging advancements.
In June 2024, Canon Medical Systems USA, Inc. entered into a strategic partnership with Hermes Medical Solutions through a Sales Agent Agreement. The partnership is designed to broaden access to innovative solutions, improve clinical outcomes, and complement Canon's Vitrea Oncology offerings with advanced theragnostic capabilities.
In July 2023, GE HealthCare extended its collaboration with Elekta to expand access to precision radiation therapy solutions in India. This partnership aims to provide comprehensive imaging and treatment offerings for cancer patients, integrating diagnostic and therapeutic solutions. The alliance is designed to enable more efficient, precise, and personalized care, which aligns with the application of elastography in oncology for tumour characterization and treatment planning